Clinical Trial Update: Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study [Phase 3]

View source ↗

Summary

Phase 3 trial assessing long-term immunity and safety of JEV IC51 (IXIARO, JESPECT) in pediatric population in non-endemic countries has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• IXIARO (inactivated Japanese encephalitis vaccine)
• JESPECT (inactivated Japanese encephalitis vaccine)

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Japanese Encephalitis | Phase 3 | Status: COMPLETED | Results posted: 2015-04-29